Sunday, February 22, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

A conversation with Dr. Samant Virk, founder of MediSprout

Dr. Virk is a Neurologist trained in interventional spine and pain management who founded the startup, MediSprout.

MediSprout connects doctors with their patients using secure two-way video through a platform that can be downloaded onto a smart device or desktop. It promotes continuity of care by keeping doctors and patients better connected between visits, providing an easy way to refill prescriptions, review test results, ask questions or simply check in on a care plan.

To collaborate with MediSprout, select the following link.

For further questions about signing up, or just to learn more about MediSprout, please email: [email protected]

For a select list of Dr. Virk’s writings, please select the articles below:

MediSprout Archives

KevinMD Archives

Will remote patient monitoring be a lifeline or a liability?

There’s no patient-centered care without patient-centered data

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply

Your email address will not be published. Required fields are marked *

Videos

2027 Medicare Advantage & Part D Advance Notice

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...

Read more

Join Our Newsletter!